The sustained still low SP is perhaps due to institutional investors still reviewing their decisions to jump in enmass and may be waiting for announcement of Ph 2 trial details. I think they can easily guess what is going to come out from the ASH presentation. However, the JNJ deal this early (before even beginning Ph 2) must have been a serious factor in their decisions to begin the review. And, the facts that there is still a substantially large short position which will be gradually taken out and that the time drug' will be coming to the market is still not very clear will keep the SP sufficiently low for them for some time and wait a bit longer to jump in enmass. It is very likely, however, that some of them may have started a gradual accumulation since the announcement of the JNJ deal. My belief is that the real SP action will come in January or later And, please note that this is just my view. Of course, for retail investors, it will be a good idea to remain a bit more patient and add more at lows.
That and a wrong idea residing in their infertile brain that they can fool others!! I often wonder why God has created such a specie!!!! Aren't these guys comparable to those brainwashed terrorists who commit suicide missions?
Perhaps the management doesn't want the SP to go up and want shorting continued so that more shares can be acquired by underwriters at cheaper price and. also, the management can award themselves with lower-priced stock options. Besides that, the money they got from JNJ must have strings attached to be spent only on cost for the trial or such other purpose, not to buyback shares!!
whether vermins have posts bashing or pushing the share price (both sides lying through the teeth) on this crummy board, the actual SP remains largely unaffected. Then one wonders, why are the vermins trying to beat each other?!! Idiots, isn't it?!!!
He has 18 up now and you have 5 down!! This is Yahoo board!! All these ups and down tell you to just quit the board because your messages are abhored!!.
Praise for OCAT doesn't mean no confidence in Geron!! Both companies are great investments. You apparently lack foresight and are ignorant of facts. You may have to take your OCAT criticism back in about a year!!
Thanks for posting the news and details on this board. My wishes for John's continued durable recovery and a long happy life for both of you. I understand how greatly you both must be feeling obliged to Tefferi; but, please do not forget to feel obliged primarily to those forgotten scientists at Geron who evolved this BT drug. they are the ones who deserve the praise primarily.
Nishith, my sincere thanks for truly an excellent response to my query. I got my answers and a bit more!!
Please keep posting whenever you see it necessary to do so because there are a number of sincere visitors of this Geron board (beside a lot of vermins!) who will benefit from your thoughts to clench their thirst of knowledge. Thanks again.
My feeling is that the plan is to get IMET licensed, as fast as they can, for use on MF patients. Once that is in hand, then, physicians will have a window opened for its use on other hematologic applications under the orphan-drug status. I think besides Scarlett and Huh at Geron, Tefferi and experts at Janssen/JNJ will make a formidable team to accelerate clinical use of IMET. I also see that this team will succeed in getting at least the FTD status granted to the MF/MDS trial by the FDA. Of course, they all, including the FDA, want to beat other global competitors in bringing up a drug to cure cancers. Those who see otherwise perhaps lack proper foresight.
Yes, Nishith, it is not a God-cure; but, like you stated, it has a great potential for use in combination regimens. Do you see these regimens will include not just other hematologic malignancies but also the solid-tumor ones? Is the telomere/telomerase concept not like hitting the nail on its head for curing cancers? OR much more is needed based on further genomic studies to come to that conclusion? Will appreciate very much if you can respond. Thanks.
Maine, it is good to see that you have been transformed from a bitter and persistent critic to a constructive poster. Thanks for the change and expressing your, I believe, sincere thoughts. However, I see that probability of the SP hitting low to mid-2s level is pretty low since Geron may announce detailed plans for the multi-center trial and may keep issuing certain positive news. Of course, since it has plenty of cash in hand, it wouldn't need any financing and, hence, will pay no attention to keep the SP in check. Generally crooked members of management often try to bring SP of their company low so that they can award themselves options at low price. I hope that is not the game the Geron management is inclined to play.
Nishith, one idiot gives you a thumb down - must be a brainwashed short. Anyhow, it's good to know that a hematologist/oncologist visits this board. Please keep posting to provide us- long-term serious investors in Geron/IMET - authentic opinions and useful technical discussions. Thanks.
If the deal with JNJ was in process all through 2014, it says a lot about who is behind the halt as well as the lift and, of course, the importance and future prospects for IMET. JNJ will not commit for a billion-dollar guarantee for a drug which has not even seen its Ph 2 trial!! Note also that Tefferi has remained silent for quite some time since his outburst against ineffectiveness of the Jakafi inhibitor. The JNJ pull on all these and its confidence in the prospects for IMET are apparent. If you see these, you will not be worried about your investment going sour.
Maine, I will not disagree with you. It's quite possible. His overall role may be lessened and, someone else even may take his place. However, he may continue to be on Geron's side, and less so on the JNJ side. Do not forget he IS at Mayo, the top outfit dealing with cancers. Of course, I stand corrected on my assumption of his all-important role. Thanks.